Section
Depression, anxiety, trauma, substance use, dementia and emerging treatments, as reported by clinical and research outlets.
846 articles · page 14 of 22 · Jan 21, 2026 – Feb 5, 2026
Archive summary Clinical
A new Yale study finds that adolescents with anxiety or depression fair better when doctors follow FDA approvals or professional treatment guidelines rather than…
Archive summary Clinical
Archive summary Clinical
February is the shortest month of the year, yet seasonal affective disorder can make it feel like being stuck in a waiting room with no ... Read moreThe post Seasonal…
Archive summary Clinical
What is post-traumatic stress disorder? In post-traumatic stress disorder (PTSD), distressing symptoms occur after one or more frightening incidents. For the most part,…
Archive summary Clinical
A study by researchers at King's College London analyzing data from more than 29 million individuals in England found that COVID-19 has had a lasting and…
Archive summary Clinical
Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (SIX: ADXN ...
Archive summary Clinical
BPC-157 hasn't been approved by the FDA. But that hasn't stopped this buzzy drug from gaining traction – and attention from MAHA.
Archive summary Clinical
EINPresswire/ -- Understanding the growing importance of sleep health reveals why the sleep disorder market is expanding so rapidly. With an increasing number of people…
Archive summary Clinical
Jelly Roll credits the lessons he learned from addiction recovery for aiding his weight-loss journey.
Archive summary Clinical
Trump administration details a new addiction initiative led by HHS Secretary Kennedy emphasizing faith-based groups, tough love and recovery.
Archive summary Clinical
(NaturalNews) A major scientific review concludes that physical exercise can be as effective as psychological therapies like cognitive behavioral therapy in all...
Archive summary Clinical
American Well (NYSE:AMWL – Get Free Report) and MSP Recovery (NASDAQ:MSPR – Get Free Report) are both small-cap medical companies, but which is the better stock? We will…
Archive summary Clinical
Researchers have found that key brain cells may be damaged in overdose, and OUD itself resembles near-drowning victims. Serial neurological evaluations and neurorehab…
Archive summary Clinical
Archive summary Clinical
Flow Neuroscience announced FDA approval of its Flow at-home brain-stimulation device for treating major depressive disorder, marking the first time American clinicians…
Archive summary Clinical
In 2023, the United States recorded over 110,000 drug-related deaths, driven largely by fentanyl, a synthetic opioid 50 times more potent than heroin. However, the…
Archive summary Clinical
Rejoyn, developed by Otsuka Precision Health in partnership with Click Therapeutics, is the first-and-only prescription digital therapeutic FDA-cleared for treating…
Archive summary Clinical
Fentanyl has caused approximately 266,000 deaths in the United States since 2021 and now drives roughly two-thirds or more of all overdose fatalities. The nation's…
Archive summary Clinical
A cross-sectional study of treatment-seeking individuals with opioid dependence in India reveals significant comorbidity between depression and anxiety, with…
Archive summary Clinical
The American Medical Association released a report highlighting progress but persistent challenges in addressing the nation's overdose epidemic. Opioid-related deaths…
Archive summary Clinical
All 50 states, plus the District of Columbia and four U.S. territories, have reached a historic $7.4 billion settlement with Purdue Pharma, the maker of OxyContin, the…
Archive summary Clinical
Anxiety is one of the most treatable mental health conditions, though clinical anxiety disorder emerges when worry becomes excessive, difficult to control, and…
Archive summary Clinical
Solvonis Therapeutics PLC announced positive preclinical data for SVN-15, its lead compound positioned as a potential first-in-class depression treatment that targets…
Archive summary Clinical
LIV Recovery Center, a behavioral and mental health treatment clinic in Alpharetta, Georgia, is advancing its dual diagnosis treatment services to better serve…
Archive summary Clinical
Archive summary Clinical
Solvonis Therapeutics has announced promising preclinical trial data for its lead molecule, SVN-015, a potential breakthrough depression treatment. The compound has…
Archive summary Clinical
A major new study published in BMJ Mental Health has found that transcranial magnetic stimulation (TMS), which applies magnetic energy to the brain, can be a…
Archive summary Clinical
AtaiBeckley Inc., a clinical-stage biotechnology company, announced its participation in the 64th Annual Meeting of the American College of Neuropsychopharmacology held…
Archive summary Clinical
The FDA has granted Breakthrough Device designation to XCSITE, a non-invasive brain stimulation platform developed by Pulvinar Neuro for treating major depressive…
Archive summary Clinical
Dr. Elyse Stevens, a primary care and addiction medicine doctor in New Orleans, built a reputation for taking on complex medical cases including people battling…
Archive summary Clinical
Sutter Health announced the launch of the SAINT neuromodulation system at Sutter Center for Psychiatry in Sacramento, making Sutter the first in the greater Sacramento…
Archive summary Clinical
A recent study outlines how students' experiences of victimization in school are related to higher reports of depressive symptoms.
Archive summary Clinical
Bunnie XO shares her harrowing experience with an experimental weight-loss drug, describing severe depression and suicidal thoughts during treatment.
Archive summary Clinical
Archive summary Clinical
Officials of the Dunn County Treatment Court recently reported that 2025 was a successful year in helping individuals overcome addiction and rebuild their lives through…
Archive summary Clinical
Strengthens clinical and regulatory guidance as PSX-001 advances to its next phase of developmentMELBOURNE, Australia and NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) ...
Archive summary Clinical
Adjunctive lumateperone 42 mg has demonstrated broad symptom improvement for patients with treatment-resistant major depressive disorder (MDD), according to analyses of…
Archive summary Clinical
People who interact with chatbots for emotional support or other personal reasons are more likely to report symptoms of depression or anxiety, a new study finds. The…
Archive summary Clinical
DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative…
Archive summary Clinical
For millions of individuals worldwide, depression is not just a passing sadness—it is a persistent, life-altering condition. While traditional antidepressants offer…